Searchable abstracts of presentations at key conferences in endocrinology

ea0049ep34 | Adrenal cortex (to include Cushing's) | ECE2017

The treatment with dual release hydrocortisone in patients with adrenal insufficiency: correlation between change of the evening cortisol exposure time profile and change in metabolic profile, depression status and quality of life

Simeoli Chiara , Ferrigno Rosario , Pivonello Claudia , Auriemma Renata Simona , Negri Mariarosaria , Di Gennaro Gilda , Iacuaniello Davide , De Martino Maria Cristina , Colao Annamaria , Pivonello Rosario

Conventional glucocorticoids (CGCs) are unable to mimic physiological cortisol rhythm in adrenal insufficiency (AI), resulting in increased metabolic morbidity and impaired quality of life (QoL). Non-physiological cortisol pattern and elevated evening cortisol levels may be responsible for the increased risk of metabolic disorders observed in AI patients under CGCs. Once daily dual-release-hydrocortisone (DR-HC), which better reproduces physiological daily cortisol profile, si...

ea0070aep530 | Endocrine-related Cancer | ECE2020

Reversal effect of Vitamin D (VitD) on exosome-mediated everolimus resistance (EveR) in hepatocellular carcinoma (HCC) cell line: A molecular study

Gentile Annalisa , Negri Mariarosaria , Montò Tatiana , Patalano Roberta , de Angelis Cristina , Simeoli Chiara , Ferrigno Rosario , Cristina De Martino Maria , Simona Auriemma Renata , Colao Annamaria , Pivonello Rosario , Pivonello Claudia

Cancer exosomes emerged as important mediators of cancer drug resistance. Drug exposure-mediated EveR in HCC cell lines can be reversed by VitD pre- and co-treatment. The current study aimed to investigate whether cancer exosomes from EveR HCC cell line are able to induce EveR in parental cells and whether VitD may activate reversal effect on exosome-mediated EveR.To this purpose, parental JHH-6 and EveR JHH-6 cell line were used. The uptakeof exosomes, ...

ea0016s24.2 | State of the art in the therapy of pituitary disease | ECE2008

Medical therapy of Cushing’s disease

Pivonello Rosario

The first-line therapy of Cushing’s disease (CD) is pituitary surgery, whereas pituitary radiotherapy and bilateral adrenalectomy represent alternative treatments for patients not cured by surgery. Medical therapy has a minor role in the management of CD, and it is mainly based on the use of two different categories of drugs, the adrenal-blocking drugs, which act at the adrenal level, and the neuromodulatory drugs, which act at the pituitary level. These drugs are not usu...

ea0073ap4 | Clinical Endocrinology Trust Lecture | ECE2021

Advances on complications and therapy of cushing’s syndrome

Pivonello Rosario

In the last decade, new evidence on Cushing’s syndrome (CS) complications and therapies have gradually emerged. CS is associated with well known systemic complications, mainly including metabolic syndrome, cardiovascular disease, immune and infectious disorders, skeletal diseases, neuropsychiatric disorders, as well as impairment of gonadal function with impact on reproduction and sexuality. However, more recently several studies specifically focused on muscle and brain s...

ea0081ep700 | Pituitary and Neuroendocrinology | ECE2022

A Delphi panel of Italian endocrinologists to define the unmet needs on the current management of Cushing’s Syndrome

Pivonello Rosario , Carla Scaroni , Polistena Barbara , Migliore Antonio , Giustina Andrea

Introduction: Cushing’s Syndrome (CS) requires an accurate diagnosis, patient-tailored treatments and long-term management. To define the unmet needs of patients with CS, a consensus among a panel of Italian endocrinologists was promoted. The panel involved 57 specialists with expertise in CS management.Methods: The endocrinologists were identified by convenience sampling. The survey was built around a set of statements formulated after literature r...

ea0081p679 | Pituitary and Neuroendocrinology | ECE2022

Efficacy, safety and metabolic impact of long-term pegvisomant therapy in acromegaly: results from a 10-year single center experience

Pirchio Rosa , Simona Auriemma Renata , Elena Montini Maria , Vergura Alice , Pivonello Rosario , Colao Annamaria

Pegvisomant (PEG) is effective in acromegaly control and exerts a positive impact on glucose metabolism. The current study aimed at investigating the effects of 10-years PEG treatment on disease control, pituitary adenoma size, and metabolic profile in patients with acromegaly resistant to somatostatin analogues (SRLs). Twenty-two patients (9 men,13 women, age 45.54 ± 12.83 years) treated with PEG for 10 years, in monotherapy or in combination with SRLs, were included in ...

ea0081p680 | Pituitary and Neuroendocrinology | ECE2022

Long-term pasireotide therapy: real life experience of a single referral center

Pirchio Rosa , Vergura Alice , Elena Montini Maria , Simona Auriemma Renata , Pivonello Rosario , Colao Annamaria

Pasireotide is a second-line therapy for acromegaly, that allows to obtain disease control in patients previously uncontrolled. However, pasireotide-induced hyperglycemia is of major concern. Currently, few data concerning prolonged use of pasireotide are available. The current retrospective study aimed at investigating the efficacy and safety of long-term pasireotide therapy. Sixteen consecutive patients (5 males, 11 females, age 47 ± 11 years) undergoing pasireotide for...

ea0035p885 | Pituitary Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2014

Study Design of a Phase II trial of pasireotide s.c. alone or in combination with cabergoline in patients with Cushing's disease

Feelders Richard , Pivonello Rosario , Pedroncelli Alberto , Patino Heather , Ye Moncy , Aout Mounir , Fleseriu Maria

Background: Dopamine and somatostatin receptors on corticotroph pituitary adenomas are targets for medical treatment of Cushing’s disease (CD). Data indicate synergistic effects between pasireotide and cabergoline in improving biochemical control rates and clinical features in patients with CD.Objective: To evaluate safety and efficacy of pasireotide alone or with cabergoline in patients with CD.Methods: Patients: adults with ...

ea0070aep288 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

Association between the circadian rhythm and the inhibitory effect of glucocorticoids on browning of adipocytes

Congiusta Noemi , Gesmundo Iacopo , Negri Mariarosaria , Pagliaro Pasquale , Pivonello Rosario , Penna Claudia , Ghigo Ezio , Granata Riccarda

White adipose tissue (WAT) stores excess energy as triglycerides, while brown adipose tissue (BAT) dissipates energy through heat, acting as a defense against cold and obesity and as a positive regulator of metabolic functions. The thermogenic function of BAT is mainly regulated by the mitochondrial uncoupling protein 1 (UCP1) in brown adipocytes. Moreover, it has been shown that chronic exposure to glucocorticoids (GC) or synthetic GC receptor (GR) agonists inhibits the activ...

ea0020p561 | Neuroendocrinology, Pituitary and Behaviour | ECE2009

Glucose tolerance and somatostatin analogues treatment in acromegaly: a 12 month open, prospective study

Colao Annamaria , Auriemma Renata S , Savastano Silvia , Galdiero Mariano , Grasso Ludovica FS , Lombardi Gaetano , Pivonello Rosario

Objective: The impact of first-line somatostatin analogues (SSA) on glucose tolerance in acromegaly was investigated during a 10 year period.Patients: One hundred and twelve patients treated with depot SSA.Outcome measures: Primary outcome measures were fasting glucose levels. Data were analyzed according with baseline glucose tolerance and disease control.Results after 12 months SSA treatment: In the 63 pati...